R. Delva

5.7k citations
99 papers · 2.5k indexed · 1 hit paper · h-index 21

R. Delva

96 papers receiving 2.5k citations

Hit Papers

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ...3152015202620182022100200300

Peers

R. Delva
Comparison fields: 5 of 99
  • Oncology 1.3k
  • Pulmonary and Respiratory Medicine 1.3k
  • Cancer Research 538
  • Reproductive Medicine 160
  • Hematology 196
Replace Roberto Petrioli with:
Roberto Petrioli Italy
Giacomo Cartenì Italy
Stephen Shibata United States
Pablo Maroto Spain
P. Fargeot France
Hideyuki Ishida Japan
Luigi Manzione Italy
Stéphane Culine France
Ingrid M.E. Desar Netherlands
Lindsey Gumbrell United Kingdom
R. Delva relative to Roberto Petrioli Italy Roberto Petrioli's profile →
Citations per field
00.5×1.5×2.1×
Roberto Petrioli · 1×
Citations per year

Countries citing papers authored by R. Delva

Since Specialization
Citations

This map shows the geographic impact of R. Delva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Delva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Delva more than expected).

Fields of papers citing papers by R. Delva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Delva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Delva. The network helps show where R. Delva may publish in the future.

Co-authorship network

The 25 scholars most cited alongside R. Delva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with R. Delva Line = papers co-authored together R. Delva links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20244
3 20211
4 20208
5 201714
6 20171
7 20173
8 201514
9 20143
10 201326
11 20128
12 200859
13 200871
14 2007135
15 200631
16 200612
17 200539
18 200218
19 200212
20 19938

About R. Delva

R. Delva is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 99 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (32 papers), Prostate Cancer Treatment and Research (28 papers), Renal cell carcinoma treatment (17 papers), Testicular diseases and treatments (13 papers), Cancer, Lipids, and Metabolism (12 papers), Colorectal Cancer Treatments and Studies (10 papers), Cancer Genomics and Diagnostics (9 papers) and Neuroblastoma Research and Treatments (9 papers). The work is most often cited by research in Oncology (1.3k citations), Pulmonary and Respiratory Medicine (1.3k citations) and Cancer Research (538 citations). R. Delva has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Érick Gamelin, M. Boisdron‐Celle, Alain Morel, Christine Chevreau, Norbert Ifrah, Véronique Guerin‐Meyer, Gwénaëlle Gravis, Alain Lortholary, F Larra and Sylvie Négrier. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026